CN117398436A

CN117398436A - Application of banana peel extract in regulation of TPH1, DDC and/or AANAT gene expression

Info

Publication number: CN117398436A
Application number: CN202311628485.4A
Authority: CN
Inventors: 林咏翔
Original assignee: BAIYUETE BIOTECHNOLOGY (SHANGHAI) CO LTD
Current assignee: BAIYUETE BIOTECHNOLOGY (SHANGHAI) CO LTD
Priority date: 2017-02-10
Filing date: 2018-02-02
Publication date: 2024-01-16
Also published as: KR102208654B1; KR20190085455A; TW201828971A; TWI664975B

Abstract

Use of banana peel extract in the manufacture of a composition, wherein the composition is for at least one of: lifting upTPH1Gene expression and promotionDDCGene expression and promotionAANATGene expression, thereby achieving treatment, prevention or regulationTPH1Genes (gene),DDCGenes and/orAANATEffects of gene-related diseases or physiological functions.

Description

Application of banana peel extract in regulation of TPH1, DDC and/or AANAT gene expression

The application is a divisional application, the application number of the original application is CN201810105114.0, the application date is 2018, 02 and 02, and the application of the banana peel extract in regulating and controlling the expression of TPH1, DDC and/or AANAT genes is disclosed.

Technical Field

The present invention relates to the use of banana peel extracts for the treatment, prevention or modulation of diseases or physiological functions associated with the TPH1 gene, DDC gene and/or AANAT gene, in particular for the promotion of melatonin (melatonine) expression, thereby treating insomnia and/or improving sleep trouble.

Background

Melatonin is a hormone secreted by the pineal gland, and has the function of regulating physiological clock. During the daytime, melatonin secretion is inhibited by light, so that the person can stay awake. At night, the secretion of melatonin can rise, so that the human body can enter a sleep state. The long-term night shift, mental stress or life state of using electronic products can lead to insufficient melatonin secretion at night, lower sleep quality, even cause sleep trouble such as insomnia, and the problems of tired feeling in the daytime, reverse day and night, lower immunity and the like, and have serious influence on daily life.

Drugs commonly used in clinic for treating sleep trouble at present are sedative hypnotics (such as benzodiazepine drugs (benzodiazepine drugs) and barbiturates (barbiturates)), and antidepressants (such as cocaine Mi Puming (clomipramine) and imipramine), but the use of the aforementioned drugs is extremely prone to addiction and side effects such as somnolence, nausea, headache, vomiting, gastrointestinal discomfort, memory impairment, rebound insomnia (rebounding insomnias), spirit absentmindedness, movement disorders, respiratory depression, i.e. straying or dreaminess may occur. At present, melatonin obtained from pine cones of bovine, or chemically synthesized melatonin is also sold on the market, but the commercial products still belong to medicines which need to be strictly controlled in many countries, even forbidden medicines because of the problems of prevalence of crazy cattle, uncertainty of safe dosage and the like. Accordingly, there is a need and urgency for continued development of drugs or methods that are effective in treating insomnia and/or improving sleep trouble, and are less prone to addiction and side effects.

It is known that melatonin expression is regulated by genes such as TPH1, DDC and AANAT. Wherein, the expression quantity of TPH1 gene, DDC gene and AANAT gene is improved to promote melatonin expression and melatonin secretion. Therefore, if the expression of TPH1 gene, DDC gene and/or AANAT gene can be improved, insomnia can be effectively treated and/or sleep trouble can be improved. The inventor researches find that the banana peel extract has the effect of improving the expression of genes such as TPH1, DDC, AANAT and the like, so that the banana peel extract can be used for treating insomnia and/or improving sleep trouble, and can be used for treating, preventing or regulating diseases or physiological functions related to the genes.

Disclosure of Invention

It is an object of the present invention to provide a method for enhancing TPH1 gene expression, enhancing DDC gene expression, and/or enhancing AANAT gene expression, comprising administering to a subject in need thereof a composition, wherein the composition comprises an effective amount of banana peel extract. The method is used for at least one of enhancing melatonin expression, promoting melatonin secretion, treating insomnia, treating disorders associated with neurometable disorders, preventing disorders associated with neurometable disorders, improving sleep trouble, regulating appetite, regulating sleep, regulating mood, regulating vasoconstriction, regulating hemostatic function, and regulating immune response. Preferably, the method is used for treating insomnia and/or improving sleep trouble.

Another object of the present invention is to provide a use of banana peel extract for the manufacture of a composition, wherein the composition is used for at least one of the following: improving TPH1 gene expression, DDC gene expression and AANAT gene expression. Wherein the composition is a pharmaceutical composition or a food composition. Preferably, the composition is for enhancing melatonin expression and/or promoting melatonin secretion.

It is still another object of the present invention to provide a composition for enhancing TPH1 gene expression, enhancing DDC gene expression, and/or enhancing AANAT gene expression, wherein the composition is a pharmaceutical composition or a food composition and comprises an effective amount of banana peel extract. Preferably, the composition is for enhancing melatonin expression and/or promoting melatonin secretion.

The pharmaceutical composition provided by the invention can be used for at least one of the following: treating insomnia, treating diseases related to nerve metabolism disorder, and preventing diseases related to nerve metabolism disorder. Preferably, the pharmaceutical composition is used for treating insomnia. The pharmaceutical composition is in a dosage form selected from the group consisting of: oral administration and transdermal administration.

The food composition provided by the invention is used for at least one of the following: improving sleep disturbance, regulating appetite, regulating sleep, regulating emotion, regulating vasoconstriction, regulating hemostatic function, and regulating immune response. Preferably, the food composition is used to improve sleep disturbance. The food composition is a health food, functional food, nutritional supplement food or special nutritional food, preferably a dairy product, meat processed product, bread, flour food, biscuit, lozenge, capsule, fruit juice, tea, sports beverage or nutritional beverage.

Detailed description of the inventionand portions of the specific embodiments are described below in order to enable those skilled in the art to make and use the invention.

Drawings

FIG. 1 shows the expression levels of human neuroblastoma TPH1 gene, DDC gene and AANAT gene in the extract group compared to the control group, wherein the "control group" was cultured in the culture broth without banana peel extract for 6 hours and the "extract group" was cultured in the culture broth with banana peel extract for 6 hours;

FIG. 2 shows the score of sleep disturbance on day 0 (i.e., before drinking banana peel extract) and day 7 (i.e., after drinking banana peel extract for 7 consecutive days), where group I is "with significant sleep disturbance", group II is "potential sleep disturbance", and group III is "without sleep disturbance");

FIG. 3 shows melatonin levels in saliva of subjects on day 7, as compared to day 0; and

FIG. 4 shows the expression levels of TPH1 gene and AANAT gene in peripheral blood mononuclear cells of the above group I to III subjects at day 7, compared to day 0.

Detailed Description

Some specific embodiments according to the present invention will be described below; this invention may, however, be embodied in many different forms without departing from the spirit thereof, and should not be construed as limited to the embodiments set forth herein or as defined in the appended claims.

As used in this specification (particularly in the claims), unless the context requires otherwise, the words "a," "an," "the," and the like are to be construed to include both the singular and the plural; by "treating" is not to be construed as treating a subject until complete recovery, but rather, it is intended to include maintaining disease progression or symptoms in a subject to a substantially static extent, increasing the rate of recovery in a subject, improving the severity of a particular condition, or improving the quality of life of a patient; by "preventing" is meant inhibiting or preventing the onset of a particular condition, or maintaining a good health state in a sensitive individual, or establishing tolerance of the individual to disease; by "modulation" is meant positive modulation (including induction, stimulation, and enhancement) or negative modulation (including inhibition, and attenuation) to direct an individual toward a normal state of the physiological function; by "individual" is meant a mammal, which may be a human or a non-human animal.

Bananas are perennial herbaceous plants, the origins of which are tropical and subtropical regions of asia, and in taiwan, mainly areas such as Yu Gaoxiong, tainan, eastern and taidong are grown. In general, the edible part of the bananas is pulp, and the banana peel is mostly discarded directly. Therefore, if the banana peel can be applied, the economic value of the banana can be improved.

The TPH1 gene is known to be mainly involved in the synthesis of serotonin, which is involved in physiological functions such as appetite, sleep, emotion, vasoconstriction, hemostatic function, and immune response. Thus, low expression of the TPH1 gene affects the aforementioned physiological functions associated with serotonin, as can be seen, for example: peter Zill et al, 2007, analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem student, the entire disclosure of which is incorporated herein by reference. Thus, if the expression of TPH1 gene can be enhanced, the aforementioned physiological functions related to serotonin can be regulated.

DDC genes are known to be involved in melatonin synthesis, and this gene deletion also causes neurometabolite disorders, see, for example: riccardo Montioli et al, A comprehensive picture of themutations associated with aromatic amino acid decarboxylase deficiency: from molecular mechanisms to therapy implications, which is incorporated herein by reference in its entirety. Thus, if the expression of the DDC gene can be enhanced, it is possible to treat a neuromorphic disorder, prevent a neuromorphic disorder, and/or regulate physiological functions associated with melatonin synthesis.

The AANAT gene is known to play an important role in melatonin synthesis, see for example: jimo Borjigin et al, 1995, incorporated herein by reference in its entirety, diurnal variation in mRNA encoding serotonin N-acetyltransferase in pineal gland. Therefore, if the expression of AANAT gene can be improved, the physiological functions related to melatonin synthesis can be regulated.

The inventor of the application researches and discovers that the banana peel extract has the effect of regulating the expression of genes such as TPH1, DDC, AANAT and the like. Accordingly, the present invention relates to the use of banana peel extracts to boost TPH1 gene expression, boost DDC gene expression, and/or boost AANAT gene expression, comprising: a composition comprising banana peel extract, use of banana peel extract in preparing a composition, and method of administering a composition comprising an effective amount of banana peel extract to a subject in need thereof, wherein the composition can enhance TPH1 gene expression, enhance DDC gene expression, and/or enhance AANAT gene expression are provided.

The banana peel extract used according to the present invention may be provided by an operation comprising the steps of: (a) Extracting banana peel with an extraction solvent to provide a crude extract; (b) Centrifuging the crude extract, and filtering the supernatant to provide a filtrate; (c) Concentrating the filtrate under reduced pressure to obtain a concentrated extract; and (d) drying the concentrated extract to obtain a dried product.

In step (a), the extraction solvent is a polar solvent and optionally contains an acid, wherein the polar solvent may be water, an alcohol (e.g., a C1-C4 alcohol), or a combination thereof, and the acid may be acetic acid, citric acid, hydrochloric acid, or a combination thereof. By reacting an acid with a polar solvent with an acid: polar solvent = 0.1-5:100 to provide the extraction solvent. For example, citric acid: water = 0.5-1:100 by volume to provide an extraction solvent. In addition, the amount of the extraction solvent is not particularly limited as long as the raw material can be uniformly dispersed. For example, an extraction solvent may be used in step (a): banana peel = 1-20:1 by volume. In one embodiment of the present invention, citric acid: water = 1:100 to provide an extraction solvent, and mixing the extraction solvent: banana peel = 6:1 by volume, and carrying out the extraction in the step (a).

In step (a), a suitable extraction time may be chosen depending on the extraction solvent employed. To use citric acid: water = 1:100 as an extraction solvent, and the extraction solvent: the volume ratio of banana peel is about 6:1, typically extraction is for at least 0.5 hours, preferably at least 1.5 hours, more preferably at least 2 hours. In addition, other operations such as heating, cooling, stirring, ultrasonic wave can be used to enhance the extraction effect before or during the step (a). For example, in one embodiment of the present invention, the stirring operation is performed before performing step (a), and step (a) is performed at 85 ℃ for 0.5 hours.

In step (c), the temperature at the time of concentrating under reduced pressure may be adjusted as necessary. For example, the reduced pressure concentration of step (c) may be carried out at 45 to 70 ℃. In one embodiment of the present invention, the reduced pressure concentration of step (c) is performed at 55.+ -. 5 ℃. The banana peel extract used in the present invention may be the concentrated extract provided in step (c) or the dried extract provided in step (d), wherein step (d) may be performed by freeze drying, spray drying, or the like. To maximize the extraction efficiency, optionally, the banana peel may be repeatedly extracted with the same or different extraction solvents before step (b) and the extracts from the multiple extractions combined to provide the crude extract from step (b); the cycle of step (b), step (c), and other operations described above may also be repeated as desired.

The composition provided by the invention is a pharmaceutical composition or a food composition. Wherein the pharmaceutical composition provided according to the present invention can be used for at least one of the following: treating insomnia, treating diseases related to nerve metabolism disorder, and preventing nerve metabolism disorder; preferably, it is used for treating insomnia. The food composition provided according to the present invention is for at least one of: improving sleep disturbance, regulating appetite, regulating sleep, regulating emotion, regulating vasoconstriction, regulating hemostatic function, and regulating immune response; preferably for improving sleep disturbance.

The pharmaceutical composition provided according to the present invention may be in any convenient form, without particular limitation, and in a corresponding convenient dosage form depending on the intended use. For example, but not by way of limitation, the pharmaceutical composition may be administered to an individual in need thereof by oral or parenteral (e.g., transdermal) administration. Wherein, depending on the use form and application, a convenient carrier may be selected to provide the pharmaceutical composition, wherein, the carrier comprises excipient, diluent, adjuvant, stabilizer, absorption retarder, disintegrant, solubilizer, emulsifier, antioxidant, binder, binding agent, tackifier, dispersant, suspending agent, lubricant, moisture absorbent, etc.

For example, in a dosage form suitable for oral administration, any pharmaceutically acceptable carrier that does not adversely affect the desired benefit of the active ingredient (i.e., banana peel extract) may be included in the pharmaceutical composition provided according to the present invention, such as: water, saline, dextrose, glycerol, ethanol or analogs thereof, cellulose, starch, sugar bentonite (sugam bentonites), and combinations of the foregoing. The pharmaceutical composition may be provided in a dosage form suitable for oral administration using any convenient method, for example: lozenges (e.g., dragees), pills, capsules, granules, powders, ointments, solutions, syrups, suspensions, tinctures and the like.

For example, the pharmaceutical composition provided according to the present invention may be in the form of a patch, an emulsion, a cream, a gel (e.g., hydrogel), a paste (e.g., dispersion paste, ointment), a spray, or a solution (e.g., suspension) for direct external use.

The pharmaceutical composition provided according to the present invention can be administered at various administration frequencies once a day, a plurality of times a day, or once a few days, depending on the requirement, age, weight, and health of the individual to be administered. In the pharmaceutical composition provided by the invention, the content ratio of the banana peel extract in the composition can be adjusted according to the actual application requirements. In addition, the pharmaceutical composition may optionally further contain one or more other active ingredients (e.g., hypnotic drugs, antidepressants, melatonin, etc.), or be used in combination with drugs containing the one or more other active ingredients, so as to further enhance the efficacy of the pharmaceutical composition or to increase the flexibility of use and formulation of the formulation, as long as the other active ingredients do not adversely affect the benefits of the active ingredients (i.e., banana peel extract) of the present invention.

Optionally, the pharmaceutical composition or food composition provided by the present invention may further contain additives in a suitable amount, such as flavoring agents, toners, colorants, etc. which can improve the oral feeling and visual feeling of the pharmaceutical composition or food composition when taken, and buffers, preserving agents, preservatives, antibacterial agents, antifungal agents, etc. which can improve the stability and storability of the pharmaceutical composition or food composition.

The food composition provided by the invention can be a health food, a functional food, a nutrition supplementing food or a special nutrition food, and can be made into products such as dairy products, meat processed products, breads, flour foods, biscuits, buccal tablets, capsules, fruit juices, teas, sports drinks, nutrition drinks and the like, but not limited to the products. Preferably, the food composition provided according to the present invention is provided in the form of a health food.

The health food, the functional food, the nutrition supplementing food and the special nutrition food provided by the invention can be eaten at different frequencies of once a day, a plurality of times a day, or the like, and are different according to the age, the weight and the health condition of an individual to be administrated. The content of banana peel extract in the health food, functional food, nutritional supplement food and special nutritional food provided according to the present invention may also be adjusted to the needs of a specific population, for example, to the daily amount to be taken.

For the health food, functional food, nutritional supplement food and/or special nutritional food provided by the invention, recommended usage amount, usage standard and condition of specific groups (such as insomnia patient, melancholy patient, pregnant woman, etc.), recommended matters taken together with other food or medicine, etc. can be marked on the outer package thereof, so that the user can take the food or food without safety doubt under the guidance of doctors, pharmacists or related practitioners. Examples of the banana peel extract and related applications in the food composition provided according to the present invention are as described above.

The present invention also provides a method for enhancing TPH1 gene expression, enhancing DDC gene expression, and/or enhancing AANAT gene expression comprising administering to a subject in need thereof a composition, wherein the composition comprises an effective amount of banana peel extract. The form of administration, route of administration, form of administration, frequency of administration, and related applications of the composition are as described above.

The invention will now be further illustrated by the following examples. These examples are provided by way of illustration only and are not intended to limit the scope of the invention. The scope of the invention is defined by the appended claims.

Examples

In the examples below, the sources of the materials used are as follows:

1. bananas: taiwan in the producing area.

2. Human neuroblastoma cells (human neuroblastoma cell; SH-SY 5Y): purchased from ATCC under product number CRL-2266.

Dmem medium: purchased from Gibco under product number 12100-038.

4. Fetal bovine serum: purchased from Gibco under product number 10438-062.

5. Penicillin/streptomycin: purchased from Gibco, product numbers 15140-122.

Rna extraction kit (RNA Extraction Kit): purchased from Geneaid.

7. Reverse transcriptase [ ]III Reverse Transcriptase): purchased from Invitrogen company.

8.KAPA SYBR FAST qPCR kit: available from KAPA Biosystems.

Step One Plus instrument: purchased from ABI corporation.

10. Melatonin detection reagent (Melatonin direct Saliva ELISA, 96T): available from IBL company under the product number RE54041.

ficoll-Paque Plus separation: purchased from GE Healthcare.

Example 1: preparation of banana peel extract

Separating the peel from the flesh of the banana and subjecting the peel to the following operations to provide an extract of the peel:

1. mixing banana peel with an extraction solvent (the volume ratio of banana peel to extraction solvent is 1:6; wherein the extraction solvent is provided in a volume ratio of citric acid: water=1:100), and extracting at 85 ℃ for 0.5 hours to provide a crude extract;

2. centrifuging the crude extract obtained in the step 1 at 5000rpm for 10 minutes, collecting supernatant, and filtering with 400 mesh filter screen to obtain a filtrate;

3. concentrating the filtrate in the step 2 under reduced pressure at 55+/-5 ℃ to provide a concentrated extract;

4. the concentrated extract of step 3 was freeze-dried to provide a dry product (i.e., banana peel extract used in the examples below).

Example 2: cell experiment

Human neuroblastoma cells were seeded on 6-well plates (2 x 10 per well) ⁵ Cells) were separated into control and extract groups (each group was duplicated three times) after culturing for 24 hours, and cultured in the following media, respectively, for 6 hours:

1. control group: DMEM medium containing 10% fetal bovine serum, 1% penicillin/streptomycin;

2. extract group: the medium of the control group was as in the case of the control group, but 15.625. Mu.g/ml of banana peel extract from example 1 was additionally added.

Thereafter, each of the above groups of cells was collected, and RNA was extracted with an RNA extraction kit, and then reverse transcribed into cDNA with reverse transcriptase. Next, the cDNA was subjected to qPCR (quantitative polymerase chain reaction) using a ABI Step One Plus instrument and KAPA SYBR FAST qPCR kit to detect the expression level of melatonin-related genes (including TPH1, DDC and AANAT) in each cell group. The relative gene expression level of the extract group was calculated based on the results of the control group (i.e., the gene expression level of the control group was set to 1-fold). The results are shown in FIG. 1.

As can be seen from FIG. 1, the expression levels of TPH1, DDC and AANAT gene were significantly increased in the extract group compared to the control group, wherein the expression level of AANAT gene was even as high as 3.33 times. The results show that the banana peel extract can indeed improve the expression level of TPH1, DDC and AANAT genes, so that the expression of melatonin can be effectively improved, the secretion of melatonin can be promoted, and the effects of treating insomnia and improving sleep trouble can be achieved.

Example 3: human body experiment

(3-1) sample collection

The sleep state of the subjects was evaluated after recruiting the volunteer subjects (excluding hypnotics, hypoglycemic agents, and pregnant women), and classifying the subjects into three groups (each group of one person) of "having significant sleep trouble (hereinafter referred to as" group I ")", "potential sleep trouble (hereinafter referred to as" group II ")", and "no sleep trouble (hereinafter referred to as" group III ")". Before the start of the experiment, each subject was asked to fill out a sleep questionnaire (i.e., day 0 sleep questionnaire, the content of the questionnaire is shown in table 1 below), and saliva and blood (i.e., day 0 saliva and blood) of each subject were collected for use in the subsequent experiment. Next, subjects were asked to drink a drink containing 200 mg of the banana peel extract obtained in example 1 after dinner every day for 7 days (i.e., each subject took the drink 7 times). Thereafter, each subject was again asked to fill out a sleep questionnaire (i.e., day 7 sleep questionnaire, the content of the questionnaire was the same as day 0 sleep questionnaire), and saliva and blood (i.e., day 7 saliva and blood) from each subject was collected for use in subsequent experiments.

Table 1:

(3-2) sleep disturbance score assessment

The day 0 sleep questionnaire and the day 7 sleep questionnaire of 3-1 were analyzed, and the sleep disturbance score of each group of subjects was calculated, with 8 points as a sleep disturbance benchmark (i.e., more than 8 points represent sleep disturbance). The results are shown in FIG. 2.

As can be seen from fig. 2, the sleep disturbance scores of the "group I" and the "group II" were significantly reduced on day 7, while the sleep disturbance score of the "group III" was not significantly changed. The results show that the banana peel extract can effectively reduce the sleep disturbance phenomenon of 'people with obvious sleep disturbance' and 'potential sleep disturbance', and does not have adverse effect on 'people without sleep disturbance'.

(3-3) melatonin assessment

Saliva of each group of subjects provided by 3-1 on day 0 and day 7 was taken and tested with a melatonin test reagent to measure the melatonin content in the saliva (which is commonly affected by the expression and secretion of melatonin). The relative melatonin content on day 7 was calculated based on the results on day 0 (i.e., the melatonin content on day 0 was set to 1 time). The results are shown in FIG. 3.

As can be seen from fig. 3, the melatonin content in saliva of "group I", "group II" and "group III" was significantly increased on day 7 compared to day 0. The results show that the banana peel extract can effectively improve the melatonin expression and promote melatonin secretion, thereby achieving the effects of treating insomnia and improving sleep trouble.

(3-4) assessment of melatonin-related Gene expression level

Day 0 and day 7 blood from each group of subjects provided in 3-1 was taken and peripheral blood mononuclear cells (Peripheral blood mononuclear cell, PBMCs) were isolated therefrom with Ficoll-Paque Plus isolate. Next, the expression level of melatonin-related genes (including TPH1 and AANAT) in peripheral blood mononuclear cells of each group of subjects was examined in the analytical manner of example 2. The relative expression amount of the gene on day 7 was calculated based on the result on day 0 (i.e., the gene expression amount on day 0 was set to 1-fold). The results are shown in FIG. 4.

As can be seen from FIG. 4, the expression levels of TPH1 and AANAT genes were increased on both "group I" and "group II" on day 7, as compared to day 0. The banana peel extract provided by the invention can effectively improve the expression level of TPH1 and AANAT genes of 'people with obvious sleep trouble' and 'potential sleep trouble', can effectively improve the melatonin expression and promote the melatonin secretion, and achieves the effects of treating insomnia and improving sleep trouble.

The above results show that the banana peel extract of the present invention can indeed increase the expression level of TPH1, DDC and AANAT genes, and thus can be used for increasing melatonin expression and promoting melatonin secretion, and also can be used for at least one of treating insomnia, improving sleep trouble, treating diseases related to neuromorphic disorders, preventing diseases related to neuromorphic disorders, regulating appetite, regulating sleep, regulating emotion, regulating vasoconstriction, regulating hemostatic function, and regulating immune response, especially for treating insomnia and/or improving sleep trouble.

Claims

1. Use of banana peel extract in the manufacture of a composition characterized by: the banana peel extract is provided by extracting banana peel with a polar solvent containing an acid, the composition being used for at least one of: lifting upTPH1Gene expression and promotionDDCGene expression and promotionAANATGene expression.

2. The use according to claim 1, characterized in that: the composition is used for improving melatonin expression and/or promoting melatonin secretion.

3. Use according to claim 1 or 2, characterized in that: the composition is a pharmaceutical composition or a food composition.

4. A use according to claim 3, wherein: the composition is a pharmaceutical composition, and the pharmaceutical composition is for at least one of: treating insomnia, treating diseases related to nerve metabolism disorder, and preventing diseases related to nerve metabolism disorder.

5. The use according to claim 4, wherein: the pharmaceutical composition can be used for treating insomnia.

6. The use according to claim 4, wherein: the pharmaceutical composition is in a dosage form selected from the group consisting of: oral administration and transdermal administration.

7. A use according to claim 3, wherein: the composition is a food composition, and the food composition is for at least one of: improving sleep disturbance, regulating appetite, regulating sleep, regulating emotion, regulating vasoconstriction, regulating hemostatic function, and regulating immune response.

8. The use according to claim 7, wherein: the food composition is used for improving sleep disturbance.

9. The use according to claim 7, wherein: the food composition is a health food, functional food, nutritional supplement food or special nutritional food.

10. The use according to claim 7, wherein: the food composition is a dairy product, meat processed product, bread, flour food, biscuit, lozenge, capsule, fruit juice, tea, sports drink, or nutritional beverage.